Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure

In patients with symptomatic congestive heart failure receiving optimal therapy with an angiotensin-converting enzyme (ACE) inhibitor and a β-blocker, the impact of using an angiotensin receptor blocker on submaximal exercise capacity and on neurohumoral activation at rest and during stress has not...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American heart journal 2005-05, Vol.149 (5), p.938.e1-938.e7
Hauptverfasser:	Blanchet, Martine, Sheppard, Richard, Racine, Normand, Ducharme, Anique, Curnier, Daniel, Tardif, Jean-Claude, Sirois, Pierre, Lamoureux, Marie-Catherine, De Champlain, Jacques, White, Michel
Format:	Artikel
Sprache:	eng
Schlagworte:	ACE inhibitors Adrenergic beta-Antagonists - therapeutic use Angiotensin II - antagonists & inhibitors Angiotensin II - blood Angiotensin-Converting Enzyme Inhibitors - therapeutic use Biological and medical sciences Biphenyl Compounds - therapeutic use Blood pressure Cardiology. Vascular system Cardiovascular disease Coronary vessels Double-Blind Method Drug therapy Drug Therapy, Combination Enalapril - therapeutic use Enzymes Exercise Exercise Tolerance - drug effects Female Heart Heart failure Heart Failure - blood Heart Failure - drug therapy Heart failure, cardiogenic pulmonary edema, cardiac enlargement Humans Lactic Acid - blood Male Medical sciences Middle Aged Mortality Norepinephrine - blood Population Prospective Studies Rest Tetrazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!